Effectiveness of oxcarbazepine in symptomatic treatment of painful diabetic neuropathy.
BACKGROUND
Both basic and clinical research has demonstrated that antiepileptic drugs can be effective in alleviating neuropathic pain. It was hypothesized that oxcarbazepine might be effective in reducing the symptoms of painful diabetic neuropathy.


OBJECTIVE
To investigate the long-term efficacy and safety of oxcarbazepine in symptoms of painful diabetic neuropathy.


METHODS
This study included thirty-eight painful diabetic neuropathy patients, which were screened with clinical assessment and electrophysiological studies. The efficacy and safety of oxcarbazepine were evaluated according to the changes in pain intensity and social interference subitems scores of Short-form Brief Pain Inventory besides electrophysiological studies at the end of six months of the treatment.


METHODS
The Students t, Mann-Whitney U and Rank Sum test and Chi-square tests were applied to examine variables differences. The level of statistical significance was chosen to be P<0.05.


RESULTS
A significant difference was found in all of subitems of pain intensity and social interference at the end of the study according to the baseline scores. Improvement was observed in 52.7%, 63.1%, 55.3% and 63.2% of patients for worst, least, average and pain right now at the end of six months, respectively. Improvement was observed as 60.6%, 63.2%, 52.6%, 60.5%, 68.4% and 63.2% for general activity, mood, walk, work, people relations, sleep and life enjoyment subitems, respectively. None of these patients had any prominent side effect leading to discontinue the treatment.


CONCLUSIONS
Long-term oxcarbazepine treatment was found to be effective and safe in the symptoms of painful diabetic neuropathy.
Erdemoglu
A Kemal
AK
Department of Neurology, Faculty of Medicine, University of Kirikkale, Turkey. akerdemoglu@yahoo.com
Varlibas
Ayhan
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078330:Oxcarbazepine; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010147:Pain Measurement
D002220:Carbamazepine; D000078330:Oxcarbazepine